Lipocine Inc. (LPCN)
NASDAQ: LPCNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LPCN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $16.39M
- EPS (TTM)
- -$1.32
- Dividend yield
- None
- 52-week range
- 1.36 – 12.37
- Day range
- 1.43 – 1.55
- Volume / Avg
- 215.73K / 1.84M
- Beta
- —
- Shares outstanding
- 11.07M
52-week range
LPCN stock today
Shares of Lipocine (LPCN) finished lower on Nov 20 at $1.48, a drop of 1.33% or $0.02 per share, versus the S&P 500's 3.70% decline. Trading was light, with 215.73K shares changing hands, about 12% of the average daily volume. Shares are 88.0% below their 52-week high of $12.37, set on Jan 15, 2026 and 8.8% above the 52-week low of $1.36, near the bottom of the past year's range.
LPCN is down 81.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.2%. Lipocine has posted a net loss over the last twelve months (EPS of -$1.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lipocine
Company profileLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mahesh V. Patel Ph.D.
- Headquarters
- Salt Lake City, UT
- Employees
- 14
- Website
- lipocine.com
Financial highlights
Full financialsIn fiscal 2025, Lipocine generated $2.0 million in revenue, down 82.3% from fiscal 2024, its first annual decline since 2023. Lipocine reported a net loss of $9.6 million, compared with net income of $8,352 a year earlier. Operating margin was -524.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.98M | $11.20M | $-2.85M | $500.00K | $16.14M |
| Growth | -82.35% | +492.80% | -670.16% | -96.90% | — |
| Net income | $-9.63M | $8.35K | $-16.35M | $-10.76M | $-634.40K |
| EPS (diluted) | $-1.69 | — | $-3.14 | $-2.15 | $-0.01 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$5.00+237.84%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.08 vs $-0.39
- Surprise
- +79.49%
LPCN news
All LPCN newsLipocine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SHPHShuttle Pharmaceuticals Holdings Inc. | 3.49 | -10.51% | $16.63M | vs LPCN |
| AKTXAkari Therapeutics plc ADS | 7.18 | +7.00% | $16.70M | vs LPCN |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs LPCN |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs LPCN |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 3.28 | -2.35% | $15.76M | vs LPCN |
| KTTAPasithea Therapeutics Corp. | 0.4787 | -0.48% | $17.59M | vs LPCN |
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs LPCN |
| CELUCelularity Inc. Class A | 0.463 | -1.05% | $15.02M | vs LPCN |
Indexes, lists and sector
Lipocine stock FAQ
What is Lipocine's stock price today?
LPCN last traded at $1.48 as of Nov 20, 4:00 PM EST, down 1.33% on the day. Prices are delayed at least 15 minutes.
Does Lipocine pay a dividend?
No. Lipocine does not currently pay a regular cash dividend.
Who is Lipocine's CEO?
Dr. Mahesh V. Patel Ph.D. is the chief executive officer of Lipocine Inc., which has about 14 employees.
Has LPCN ever split its stock?
Yes. The most recent LPCN stock split was a 1-for-17 split on May 12, 2023.
What is the LPCN 52-week high?
The 52-week high for LPCN is $12.37 and the 52-week low is $1.36. The stock is currently 88.0% below its high.